Avammune Therapeutics Profile Photo

Avammune Therapeutics

(ATEN PORUS LIFESCIENCES PRIVATE LIMITED)

16 Published Patents

Founded in 2013

About Avammune Therapeutics

Avammune Therapeutics is a startup that develops non-nucleotidic small molecule inhibitors for the treatment of cancer and auto-immune diseases. The molecules are intended to inhibit a negative regulator of the STING pathway called Ectonucleotide Pyrophosphatase I (ENPP1).

Key Founders and Directors of Avammune Therapeutics

Angel Networks & VC Investors of Avammune Therapeutics

+5 more funds

Frequently Asked Questions (FAQ)

When was Avammune Therapeutics founded?

Avammune Therapeutics was founded in the year 2013.

What is the legal name of Avammune Therapeutics?

The legal name of Avammune Therapeutics is Aten Porus Lifesciences Private Limited.

Who are the founders of Avammune Therapeutics?

Avammune Therapeutics is founded by Aditya Kulkarni, Arun B Papaiah and Srinivasan Namala.

Which VC Investors & Angel Networks funded Avammune Therapeutics?

Avammune Therapeutics is funded by VC Investors & Angel Networks like 1crowd and 5 others.

Which Incubators & Accelerators supported Avammune Therapeutics?

Avammune Therapeutics is supported by Incubators & Accelerators like Centre For Cellular And Molecular Platforms (C-camp), Bengaluru and 1 other.

What are the focus areas of Avammune Therapeutics?

The key focus areas of Avammune Therapeutics are Ava-adr Drug Series - Adar1 Inhibitors and 5 others.

Who are Avammune Therapeutics's competitors?

Possible competitors of Avammune Therapeutics may include 24 Media Fusion (P) Ltd., Acubiosys, Althion and 7 others.

Get Access to Complete Information

Signup Now

YNOS is not associated with any of the entities (organisations / people) mentioned in this page. Information provided here has been curated from multiple public as well as proprietary sources. All efforts have been taken to make it accurate and complete. If details are insufficient or not accurate, kindly suggest edits